Financial Data and Key Metrics Changes - The company reported its twelfth consecutive quarter of profitability, achieving a total revenue of $263.6 million, which is 3.6% higher than the previous year despite a 0.5% decrease in total block hours [13][14] - The GAAP pretax margin was 3.2%, and the adjusted pretax margin was 3.9%, marking the third consecutive quarter of total revenue growth year-over-year and improvement in pretax margin [13] - The company expects to generate approximately $1.5 billion in revenue, $300 million in EBITDA, and $2.5 in EPS by 2027 [10][11] Business Line Data and Key Metrics Changes - Revenue from the cargo segment grew 36.8% year-over-year to $34.8 million, marking the highest quarterly cargo revenue in the company's history [16] - Scheduled service revenue, which includes both scheduled and charter businesses, decreased by 0.8% year-over-year due to a significant reduction in scheduled service operations, with scheduled service ASMs declining by 6.2% [14][15] - Charter revenue increased by 6.4% to $54.3 million, supported by a 7.9% increase in charter block hours [15][16] Market Data and Key Metrics Changes - The company anticipates third-quarter total revenue to be between $250 million and $260 million, with block hours expected to increase by 5% to 8% [21] - The company noted that fuel prices decreased by 15% compared to the same period in 2024, impacting fuel reconciliation proceeds [16] Company Strategy and Development Direction - The company is focusing on growth in its cargo business, expecting to have all eight cargo additions in service by the end of the third quarter, which will double cargo revenue once fully utilized [6][14] - The strategy includes maintaining a diversified revenue stream and being nimble in capacity allocation to maximize profitability [34][36] - The company plans to continue building its balance sheet and is open to organic growth opportunities arising from industry disruptions [34][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver industry-leading profitability throughout all cycles, despite current challenges in scheduled service due to rapid cargo growth [5][6] - The management highlighted that the peak summer months could absorb more capacity than was delivered, with expectations of margin expansion as scheduled service is rebuilt [9][10] - Management noted that the current demand for their product remains strong, with bookings for the winter peak period looking promising [55][101] Other Important Information - The company expects to pay down an additional $44 million in debt by the end of the year, with total debt and lease obligations at $562 million at the end of Q2 [20][21] - The company has a share repurchase authorization of $25 million from its Board of Directors [21] Q&A Session Summary Question: Can you discuss the path to $2.50 EPS and industry conditions? - Management indicated that long-term revenue forecasts include a general inflation tailwind of about 3% and are based on stable unit revenue performance and predictable costs [24][25] Question: How is the peak season shaping up with Amazon? - Management noted delays in asset utilization due to aircraft preparation, but they expect to reach operational capacity soon [26][27] Question: What is the strategy regarding industry capacity and competition? - The company aims to execute well and look for organic growth opportunities while maintaining a strong balance sheet [34][36] Question: Can you provide insights on charter business modeling? - Management explained that charter business consists of long-term commitments and ad hoc opportunities, with expectations for stable margins [88][89] Question: How does the company view capital allocation? - The company plans to balance between shareholder returns and growth opportunities, focusing on free cash flow generation [66][68] Question: What are the expectations for the upcoming quarters? - Management expects Q4 to be strong due to peak holiday travel, with a gradual recovery in margins anticipated [74][75]

Company Overview - Houlihan Lokey has 33 locations worldwide and 2,677 global employees, including 347 managing directors[11] - The firm's revenue reached $2.5 billion for the last twelve months ended June 30, 2025[11] - The average tenure of the Executive Management Team and Operating Committee Team is over 25 years[15] - No single individual generated more than 2% of the firm's revenues[24] Financial Performance - The company experienced strong revenue growth with a five-year Compound Annual Growth Rate (CAGR) of 16%[19] - Adjusted pre-tax income grew at a CAGR of 17% over the same five-year period[19] - For the three months ended June 30, 2025, revenues were $605.349 million compared to $513.609 million for the three months ended June 30, 2024[130] - Adjusted net income for the three months ended June 30, 2025, was $148.005 million, or $2.14 per diluted share, compared to $84.305 million, or $1.22 per diluted share for the three months ended June 30, 2024[130] Business Segments - Corporate Finance generated $1.597 billion in revenue, representing 64% of the total, Financial Restructuring $555 million (23%), and Financial and Valuation Advisory $329 million (13%) for the last twelve months ended June 30, 2025[71] - The Corporate Finance group closed 573 transactions, Financial Restructuring 147, and Financial and Valuation Advisory 2,460 fee events[71] - The company has increased its Managing Director Headcount by a CAGR of 9% over the last 20 years[59]

Core Viewpoint - Johnson & Johnson (J&J) is facing multiple challenges including declining sales in its MedTech segment, loss of exclusivity for its drug Stelara, and ongoing talc lawsuits, while also navigating a volatile macroeconomic environment [1][2][26] Company Strengths and Weaknesses - J&J's diversified business model is a significant strength, operating through pharmaceuticals and medical devices with over 275 subsidiaries, which helps it withstand economic cycles [4] - The separation of its Consumer Health business into Kenvue allows J&J to focus on its core pharmaceutical and medical device operations [5] Innovative Medicine Unit - J&J's Innovative Medicine unit is experiencing growth, with sales increasing by 4.4% in Q1 2025 despite the loss of exclusivity for Stelara [6] - The company anticipates generating over $57 billion in sales from the Innovative Medicines segment in 2025, with expected growth of 5-7% from 2025 to 2030 [7] - J&J has identified 10 new products with potential peak sales of $5 billion, including cancer drugs and pipeline candidates [8] Patent Expiration and Sales Impact - The loss of U.S. patent exclusivity for Stelara in 2025 is expected to significantly impact sales, which were $10.36 billion in 2024, with a projected decline of 33.7% in Q1 2025 [9][10] - The introduction of biosimilars is anticipated to further erode Stelara's sales throughout 2025 [11] MedTech Segment Challenges - J&J's MedTech sales are facing headwinds, particularly in the Asia Pacific region, with challenges from China's volume-based procurement program and competitive pressures [12][13] - No improvement is expected in the Asia Pacific region for 2025, with ongoing impacts from the VBP program [13] Legal Issues - J&J is dealing with over 62,000 lawsuits related to its talc-based products, which allege that these products contain asbestos [14] - A bankruptcy court recently rejected J&J's proposed plan to settle these lawsuits, forcing the company to revert to traditional legal proceedings [15] Stock Performance and Valuation - J&J's stock has outperformed the industry year-to-date, rising 6.8% compared to a 2.7% decline in the industry [16] - The stock is reasonably priced with a price/earnings ratio of 14.25, slightly below the industry average of 14.79 [19] Future Outlook - J&J considers 2025 a "catalyst year" for growth, expecting operational sales growth to accelerate in the second half of the year [24] - The company has a promising R&D pipeline and has recently made acquisitions to strengthen its market position [25]

Investor Presentation May 2025 Disclaimers Forward-Looking Information This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation may be forward-looking statements. The words "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" and other expressions that are predictions of or indicate future events ...